RCKT vs. RCUS, DRNA, AUPH, YMAB, HRTX, ASND, LEGN, CERE, VKTX, and ITCI
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Arcus Biosciences (RCUS), Dicerna Pharmaceuticals (DRNA), Aurinia Pharmaceuticals (AUPH), Y-mAbs Therapeutics (YMAB), Heron Therapeutics (HRTX), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), and Intra-Cellular Therapies (ITCI). These companies are all part of the "medical" sector.
Arcus Biosciences (NYSE:RCUS) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk.
Rocket Pharmaceuticals has lower revenue, but higher earnings than Arcus Biosciences. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 12.3% of Arcus Biosciences shares are held by company insiders. Comparatively, 31.1% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Arcus Biosciences presently has a consensus price target of $41.25, indicating a potential upside of 172.28%. Rocket Pharmaceuticals has a consensus price target of $52.13, indicating a potential upside of 152.30%. Given Rocket Pharmaceuticals' higher possible upside, equities analysts clearly believe Arcus Biosciences is more favorable than Rocket Pharmaceuticals.
In the previous week, Rocket Pharmaceuticals had 17 more articles in the media than Arcus Biosciences. MarketBeat recorded 19 mentions for Rocket Pharmaceuticals and 2 mentions for Arcus Biosciences. Rocket Pharmaceuticals' average media sentiment score of 0.69 beat Arcus Biosciences' score of 0.17 indicating that Arcus Biosciences is being referred to more favorably in the media.
Rocket Pharmaceuticals has a net margin of 0.00% compared to Rocket Pharmaceuticals' net margin of -97.47%. Rocket Pharmaceuticals' return on equity of -40.98% beat Arcus Biosciences' return on equity.
Arcus Biosciences has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Rocket Pharmaceuticals received 189 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 72.18% of users gave Rocket Pharmaceuticals an outperform vote while only 64.54% of users gave Arcus Biosciences an outperform vote.
Summary
Rocket Pharmaceuticals beats Arcus Biosciences on 11 of the 17 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
